NIAID reports preliminary H1N1 vaccine data

NIH's National Institute of Allergy and Infectious Diseases reported preliminary data from two Phase II trials evaluating swine influenza A (H1N1) vaccines from CSL Ltd. (ASX:CSL) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY). At 8-10 days post-vaccination with a single 15 ug dose, CSL's H1N1 2009 intramuscular vaccine ( CSL425) and sanofi-aventis' intramuscular vaccine led to "robust" immune responses in 80% and 96% of adults ages 18-64, respectively, and in 60% and 56% of adults ages 65 and older, respectively. The double-blind, U.S., NIAID-sponsored trials each enrolled up to 450 healthy adult and elderly volunteers. The announcement was made after the close of the Australian Stock Exchange. CSL was up A$0.16 to A$34.21 on Friday. ...